Novamind Inc.

Novamind Inc.

Private Company
Public Company
Subsidiary of
Clinical Immersions
Clinical Trials, R&D


Novamind ($NM | $NVMDF | $HN2) is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Novamind is focused on three pillars: Clinical care, clinical research and a retreat network

I. Cedar Psychiatry operates four full-service outpatient mental health clinics providing a wide range of innovative treatments:

  • Administered over 5,000 ketamine treatments since opening in 2016
  • Over 2,000 Spravato™ treatments administered since the product became available in 2019
  • Novamind is one of North America’s top providers of ketamine-assisted psychotherapy and Spravato™

II. Cedar Clinical Research has significant experience in hosting phase I to IV clinical trials and is a recognized leader in clinical research focused on emerging treatment options in neuropsychiatry including psychedelic medicines

  • Led Spravato™ trials in Utah for Janssen Pharmaceuticals
  • Dr. Reid Robison, Novamind’s Chief Medical Officer, is Coordinating Investigator of MAPS’ clinical trial examining MDMA-assisted psychotherapy as a treatment for eating disorders
  • Developing novel therapeutic protocols that accompany psychedelic-assisted psychotherapy

III. Novamind is building a network of psychedelic retreats in jurisdictions with established regulations for the use of psychedelics and has strategic investments in the Netherlands-based Synthesis Institute and the Costa Rica-based Circadia Center 

  • Synthesis was founded in 2018 and has hosted medically supervised psilocybin retreats for more than 600 participants
  • Circadia expects to host its first psychedelic retreat post COVID-19